Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer

Christine M. Parseghian; Madhulika Eluri

doi:10.1158/1078-0432.CCR-25-4251

Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer

GI Medical Oncology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Colorectal cancers treated with targeted therapies frequently acquire numerous subclonal genomic alterations. Tumor mutational burden (TMB) is under investigation as a biomarker for predicting response to immunotherapy in microsatellite-stable metastatic colorectal cancer. In this study, we contextualize a recent study evaluating high plasma TMB after targeted therapy and its implications for immunotherapy.

Original language	English (US)
Pages (from-to)	999-1000
Number of pages	2
Journal	Clinical Cancer Research
Volume	32
Issue number	6
DOIs	https://doi.org/10.1158/1078-0432.CCR-25-4251
State	Published - Mar 15 2026

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-25-4251

Cite this

@article{5ada7d79a1634f1683cf13e558cdd968,

title = "Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer",

abstract = "Colorectal cancers treated with targeted therapies frequently acquire numerous subclonal genomic alterations. Tumor mutational burden (TMB) is under investigation as a biomarker for predicting response to immunotherapy in microsatellite-stable metastatic colorectal cancer. In this study, we contextualize a recent study evaluating high plasma TMB after targeted therapy and its implications for immunotherapy.",

author = "Parseghian, \{Christine M.\} and Madhulika Eluri",

note = "Publisher Copyright: {\textcopyright}2026 American Association for Cancer Research.",

year = "2026",

month = mar,

day = "15",

doi = "10.1158/1078-0432.CCR-25-4251",

language = "English (US)",

volume = "32",

pages = "999--1000",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - Beyond the Burden

T2 - Elevating Immunotherapy in Colorectal Cancer

AU - Parseghian, Christine M.

AU - Eluri, Madhulika

PY - 2026/3/15

Y1 - 2026/3/15

N2 - Colorectal cancers treated with targeted therapies frequently acquire numerous subclonal genomic alterations. Tumor mutational burden (TMB) is under investigation as a biomarker for predicting response to immunotherapy in microsatellite-stable metastatic colorectal cancer. In this study, we contextualize a recent study evaluating high plasma TMB after targeted therapy and its implications for immunotherapy.

AB - Colorectal cancers treated with targeted therapies frequently acquire numerous subclonal genomic alterations. Tumor mutational burden (TMB) is under investigation as a biomarker for predicting response to immunotherapy in microsatellite-stable metastatic colorectal cancer. In this study, we contextualize a recent study evaluating high plasma TMB after targeted therapy and its implications for immunotherapy.

UR - https://www.scopus.com/pages/publications/105033638343

UR - https://www.scopus.com/pages/publications/105033638343#tab=citedBy

U2 - 10.1158/1078-0432.CCR-25-4251

DO - 10.1158/1078-0432.CCR-25-4251

M3 - Article

C2 - 41528330

AN - SCOPUS:105033638343

SN - 1078-0432

VL - 32

SP - 999

EP - 1000

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 6

ER -

Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this